InteRNA Technologies B.V., a Nijmegen, The Netherlands-based biopharmaceutical company, closed an equity financing round of undisclosed amount.
Backers included new investors the Innovation & Investment Fund Gelderland, managed by PPM Oost, as well as other angels.
The company intends to use the capital to progress lead product candidate, miR-3157, for melanoma through preclinical studies towards clinical development.
Incorporated in December 2006 as a spin-off from the Hubrecht Institute, Utrecht, and led by Roel Schaapveld, CEO, InteRNA Technologies B.V. focuses on the development of microRNA (miRNA)-based therapeutics for oncology.
In addition to its own miR-3157 program, for which it was granted a US patent, the company intends to partner development of other compounds with selected pharmaceutical companies.